Smruthi Suryaprakash joined Boston Consulting Group in 2018. She has driven numerous efforts to build an integrated oncology knowledge base and also been integral to driving the firm’s internal knowledge efforts on the topics of clinical development and cell and gene therapy.
Since joining the firm, Smruthi has worked on clinical development (including optimizing E2E clinical trial processes, and developing strategy and business case for digitizing clinical trial processes), oncology (including developing the liquid biopsy strategy for an oncology player), and new modalities (including conducting a supply chain launch readiness assessment, and developing a five-year tech ops strategy).
While earning her PhD, Smruthi worked on developing technologies to engineer adult stem cells so they could find tumor cells and release cancer drugs locally to treat various types of tumors. Her work resulted in five publications and a patent application.
Pharma has invested billions in cell and gene therapies. Gene editing is making a case for more of this funding, but companies need to understand what they’re investing in and why.
Biopharma companies should approach the coming year with a clear view of shifting expectations and market conditions.
Once a visionary ambition, synthetic control arms are poised to take off. Now is the time for pharma companies to identify opportunities and gain experience.